EE72 A Cost-Effectiveness Analysis of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer in Portugal
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.344
https://www.valueinhealthjournal.com/article/S1098-3015(23)03474-5/fulltext
Title :
EE72 A Cost-Effectiveness Analysis of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03474-5&doi=10.1016/j.jval.2023.09.344
First page :
Section Title :
Open access? :
No
Section Order :
12372